Is AIKI or LUNA more profitable?

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Luna Innovations N/A N/A N/A

Which has stronger earnings and valuation, AIKI or DKDCA?

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio AIkido Pharma N/A N/A -$7.17M -$3.88 N/A Data Knights Acquisition N/A N/A $340K -$0.19 N/A

Is AIKI or DKDCA more profitable?

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Data Knights Acquisition N/A N/A -5.55%

Do analysts prefer ECOR or AIKI?

electroCore presently has a consensus target price of $18.00, indicating a potential upside of 117.39%. Given electroCore's stronger consensus rating and higher possible upside, equities analysts plainly believe electroCore is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score electroCore 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ECOR or AIKI more profitable?

AIkido Pharma has a net margin of 0.00% compared to electroCore's net margin of -44.08%. AIkido Pharma's return on equity of -18.21% beat electroCore's return on equity. Company Net Margins Return on Equity Return on Assets electroCore -44.08% -1,956.38% -83.30% AIkido Pharma N/A -18.21% -16.94%

Do analysts rate ANVS or AIKI?

Annovis Bio presently has a consensus target price of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation and earnings, ANVS or AIKI?

Annovis Bio is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Annovis Bio N/A N/A -$28.85M -$1.71 N/A AIkido Pharma N/A N/A -$7.17M -$3.88 N/A

Is ANVS or AIKI more profitable?

AIkido Pharma's return on equity of -18.21% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Annovis Bio N/A -318.08% -215.47% AIkido Pharma N/A -18.21% -16.94%

Do analysts recommend AIKI or NYXH?

Nyxoah has a consensus price target of $7.00, indicating a potential upside of 295.48%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than AIkido Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIkido Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Nyxoah 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Is AIKI or NYXH more profitable?

AIkido Pharma has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. AIkido Pharma's return on equity of -18.21% beat Nyxoah's return on equity. Company Net Margins Return on Equity Return on Assets AIkido Pharma N/A -18.21% -16.94% Nyxoah -543.21% -163.73% -80.24%

AIkido Pharma (AIKI) Competitors

$2.94 -0.11 (-3.61%)

As of 07/2/2026

Compare

AIKI vs. LUNA, DKDCA, ECOR, ANVS, and NYXH

Should you buy AIkido Pharma stock or one of its competitors? MarketBeat compares AIkido Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with AIkido Pharma include Luna Innovations (LUNA), Data Knights Acquisition (DKDCA), electroCore (ECOR), Annovis Bio (ANVS), and Nyxoah (NYXH).

How does AIkido Pharma compare to Luna Innovations?

AIkido Pharma (NASDAQ:AIKI) and Luna Innovations (NASDAQ:LUNA) are both small-cap commercial physical research industry companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

AIkido Pharma has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Luna Innovations has a beta of 1.91, meaning that its stock price is 91% more volatile than the broader market.

Luna Innovations has higher revenue and earnings than AIkido Pharma. AIkido Pharma is trading at a lower price-to-earnings ratio than Luna Innovations, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Luna Innovations	$116.61M	0.36	$9.28M	$0.03	41.00

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Luna Innovations'average media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Luna Innovations	Neutral

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 87.5% of Luna Innovations shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by insiders. Comparatively, 7.6% of Luna Innovations shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Luna Innovations' return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Luna Innovations	N/A	N/A	N/A

Summary

Luna Innovations beats AIkido Pharma on 8 of the 9 factors compared between the two stocks.

How does AIkido Pharma compare to Data Knights Acquisition?

AIkido Pharma (NASDAQ:AIKI) and Data Knights Acquisition (NASDAQ:DKDCA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, media sentiment, profitability, dividends, earnings, risk and institutional ownership.

10.9% of AIkido Pharma shares are held by institutional investors. Comparatively, 35.3% of Data Knights Acquisition shares are held by institutional investors. 8.6% of AIkido Pharma shares are held by company insiders. Comparatively, 45.7% of Data Knights Acquisition shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Data Knights Acquisition's return on equity of 0.00% beat AIkido Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Data Knights Acquisition	N/A	N/A	-5.55%

In the previous week, AIkido Pharma's average media sentiment score of 0.00 equaled Data Knights Acquisition'saverage media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Data Knights Acquisition	Neutral

AIkido Pharma has a beta of 0.93, indicating that its share price is 7% less volatile than the broader market. Comparatively, Data Knights Acquisition has a beta of 0.18, indicating that its share price is 82% less volatile than the broader market.

Data Knights Acquisition is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Data Knights Acquisition	N/A	N/A	$340K	-$0.19	N/A

Summary

Data Knights Acquisition beats AIkido Pharma on 6 of the 8 factors compared between the two stocks.

How does AIkido Pharma compare to electroCore?

electroCore (NASDAQ:ECOR) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

AIkido Pharma has lower revenue, but higher earnings than electroCore. electroCore is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
electroCore	$32.03M	2.15	-$13.97M	-$1.77	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

electroCore has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

26.7% of electroCore shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 13.8% of electroCore shares are owned by company insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

AIkido Pharma has a net margin of 0.00% compared to electroCore's net margin of -44.08%. AIkido Pharma's return on equity of -18.21% beat electroCore's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
electroCore	-44.08%	-1,956.38%	-83.30%
AIkido Pharma	N/A	-18.21%	-16.94%

In the previous week, electroCore's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company	Overall Sentiment
electroCore	Neutral
AIkido Pharma	Neutral

electroCore presently has a consensus target price of $18.00, indicating a potential upside of 117.39%. Given electroCore's stronger consensus rating and higher possible upside, equities analysts plainly believe electroCore is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
electroCore	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

electroCore beats AIkido Pharma on 7 of the 13 factors compared between the two stocks.

How does AIkido Pharma compare to Annovis Bio?

Annovis Bio (NYSE:ANVS) and AIkido Pharma (NASDAQ:AIKI) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Annovis Bio has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, AIkido Pharma has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market.

AIkido Pharma's return on equity of -18.21% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	-318.08%	-215.47%
AIkido Pharma	N/A	-18.21%	-16.94%

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 10.9% of AIkido Pharma shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 8.6% of AIkido Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Annovis Bio had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Annovis Bio and 0 mentions for AIkido Pharma. Annovis Bio's average media sentiment score of 0.00 equaled AIkido Pharma'saverage media sentiment score.

Company	Overall Sentiment
Annovis Bio	Neutral
AIkido Pharma	Neutral

Annovis Bio is trading at a lower price-to-earnings ratio than AIkido Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$28.85M	-$1.71	N/A
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A

Annovis Bio presently has a consensus target price of $13.50, indicating a potential upside of 583.54%. Given Annovis Bio's stronger consensus rating and higher probable upside, equities research analysts plainly believe Annovis Bio is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Annovis Bio beats AIkido Pharma on 8 of the 12 factors compared between the two stocks.

How does AIkido Pharma compare to Nyxoah?

AIkido Pharma (NASDAQ:AIKI) and Nyxoah (NASDAQ:NYXH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, profitability, dividends, media sentiment, institutional ownership, valuation, earnings and analyst recommendations.

AIkido Pharma has a beta of 0.93, suggesting that its share price is 7% less volatile than the broader market. Comparatively, Nyxoah has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

10.9% of AIkido Pharma shares are owned by institutional investors. 8.6% of AIkido Pharma shares are owned by company insiders. Comparatively, 17.1% of Nyxoah shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

AIkido Pharma has higher earnings, but lower revenue than Nyxoah. AIkido Pharma is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AIkido Pharma	N/A	N/A	-$7.17M	-$3.88	N/A
Nyxoah	$15.33M	4.48	-$101.92M	-$2.48	N/A

Nyxoah has a consensus price target of $7.00, indicating a potential upside of 295.48%. Given Nyxoah's stronger consensus rating and higher possible upside, analysts clearly believe Nyxoah is more favorable than AIkido Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AIkido Pharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Nyxoah	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

AIkido Pharma has a net margin of 0.00% compared to Nyxoah's net margin of -543.21%. AIkido Pharma's return on equity of -18.21% beat Nyxoah's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
AIkido Pharma	N/A	-18.21%	-16.94%
Nyxoah	-543.21%	-163.73%	-80.24%

In the previous week, Nyxoah had 2 more articles in the media than AIkido Pharma. MarketBeat recorded 2 mentions for Nyxoah and 0 mentions for AIkido Pharma. AIkido Pharma's average media sentiment score of 0.00 equaled Nyxoah'saverage media sentiment score.

Company	Overall Sentiment
AIkido Pharma	Neutral
Nyxoah	Neutral

Summary

Nyxoah beats AIkido Pharma on 9 of the 14 factors compared between the two stocks.

Get AIkido Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AIKI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AIKI vs. The Competition

Export

Metric	AIkido Pharma	Commercial physical research Industry	Medical Sector	NASDAQ Exchange
Market Cap	$16.13M	$22.67M	$6.92B	$12.60B
Dividend Yield	N/A	N/A	2.66%	6.52%
P/E Ratio	-0.76	20.50	27.35	24.81
Price / Sales	N/A	0.36	503.29	79.09
Price / Cash	N/A	57.23	29.65	49.23
Price / Book	0.15	0.15	11.06	6.50
Net Income	-$7.17M	-$525K	$3.57B	$336.03M
7 Day Performance	0.34%	-0.21%	2.56%	2.68%
1 Month Performance	-5.16%	-0.07%	7.39%	5.50%
1 Year Performance	-44.21%	2.47%	34.13%	25.01%

AIkido Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AIKI AIkido Pharma	N/A	$2.94 -3.6%	N/A	-44.2%	$16.13M	N/A	N/A	4
LUNA Luna Innovations	N/A	$1.24 -0.8%	N/A	+31.2%	$42.11M	$116.61M	41.33	390
DKDCA Data Knights Acquisition	N/A	$0.71 +0.1%	N/A	+21.5%	$3.68M	N/A	N/A	2	Gap Up High Trading Volume
ECOR electroCore	3.0362 of 5 stars	$8.19 -1.3%	$18.00 +119.8%	+45.4%	$67.94M	$34.90M	N/A	50
ANVS Annovis Bio	2.2611 of 5 stars	$1.95 +1.3%	$13.50 +594.1%	-18.9%	$67.39M	N/A	N/A	3

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AIKI) was last updated on 7/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, ECOR, ANVS, and NYXH

How does AIkido Pharma compare to Luna Innovations?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Summary

How does AIkido Pharma compare to electroCore?

Summary

How does AIkido Pharma compare to Annovis Bio?

Summary

How does AIkido Pharma compare to Nyxoah?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

AIkido Pharma (AIKI) Competitors

AIKI vs. LUNA, DKDCA, ECOR, ANVS, and NYXH

How does AIkido Pharma compare to Luna Innovations?

Which has more volatility & risk, AIKI or LUNA?

Which has higher earnings & valuation, AIKI or LUNA?

Does the media prefer AIKI or LUNA?

Do insiders and institutionals hold more shares of AIKI or LUNA?

Is AIKI or LUNA more profitable?

Summary

How does AIkido Pharma compare to Data Knights Acquisition?

Do insiders & institutionals hold more shares of AIKI or DKDCA?

Is AIKI or DKDCA more profitable?

Does the media refer more to AIKI or DKDCA?

Which has more risk & volatility, AIKI or DKDCA?

Which has stronger earnings and valuation, AIKI or DKDCA?

Summary

How does AIkido Pharma compare to electroCore?

Which has preferable valuation & earnings, ECOR or AIKI?

Which has more risk & volatility, ECOR or AIKI?

Do insiders and institutionals believe in ECOR or AIKI?

Is ECOR or AIKI more profitable?

Does the media prefer ECOR or AIKI?

Do analysts prefer ECOR or AIKI?

Summary

How does AIkido Pharma compare to Annovis Bio?

Which has more volatility & risk, ANVS or AIKI?

Is ANVS or AIKI more profitable?

Do institutionals and insiders believe in ANVS or AIKI?

Does the media favor ANVS or AIKI?

Which has preferable valuation and earnings, ANVS or AIKI?

Do analysts rate ANVS or AIKI?

Summary

How does AIkido Pharma compare to Nyxoah?

Which has more risk and volatility, AIKI or NYXH?

Do insiders and institutionals believe in AIKI or NYXH?

Which has stronger earnings & valuation, AIKI or NYXH?

Do analysts recommend AIKI or NYXH?

Is AIKI or NYXH more profitable?

Does the media favor AIKI or NYXH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AIKI vs. The Competition

AIkido Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools